糖皮质激素在SARS、MERS治疗中的应用进展及对COVID-19治疗的启示

COVID-19是一种新发的急性呼吸道传染性疾病，其病原与严重急性呼吸综合征（severe acute respiratory syndrome, SARS）和中东呼吸综合征（Middle East respiratory syndrome, MERS）的病原同为冠状病毒，目前针对COVID-19的治疗尚缺乏有效的抗病毒药物。糖皮质激素广泛应用于危重症患者的救治，但其使用有可能带来各种不良反应，甚至危及患者生命，如何适时适量应用糖皮质激素一直是针对这类疾病治疗的争论焦点之一。本文对既往SARS、MERS等病毒性肺炎治疗中糖皮质激素使用情况进行综述，以期为COVID-19治疗提供借鉴。

Advances of corticosteroids therapy in SARS and MERS and implications for COVID-19

COVID-19 is an emerging acute infectious diseases in respiratory tract. The pathogen of COVID-19, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) is all coronavirus. There is no specific antiviral drugs for COVID-19 at present. The corticosteroids have been widely used in the treatment of critically ill patients, whereas the application of corticosteroids may give rise to adverse reactions and can be life-threatening. When and how to initiate therapy with corticosteroids at rational doses have always been the focus during the treatment of these diseases. The present paper summarizes the application of corticosteroids in previous treatments of viral pneumonia such as SARS and MERS, in order to give some hints for the treatment of COVID-19.